Holen Sie sich die Stockscreener-App
1.375
1.85%
0.025
Handel nachbörslich:
1.38
0.005
+0.36%
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen (OCGN) Q2 2026 Earnings Call Transcript - AOL.com
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts - marketbeat.com
Q2 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
symbol__ Stock Quote Price and Forecast - cnn.com
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen Inc (NASDAQ: OCGN) Stock Price, News & Analysis - Kalkine
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen (OCGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen at Canaccord Genuity’s 46th Annual Growth Conference: late-stage push - Investing.com Canada
Research Analysts Issue Forecasts for Ocugen Q3 Earnings - MarketBeat
What is Noble Financial's Forecast for Ocugen Q3 Earnings? - MarketBeat
Ocugen (OCGN) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN - MarketBeat
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls - Yahoo Finance
Ocugen Inc (OCGN) Stock News Today - TradingKey
State Street Corporation (NYSE: STT) reports 6.3% beneficial stake in Ocugen - Stock Titan
Ocugen Q2 Earnings Call Highlights - MarketBeat
Ocugen (NASDAQ:OCGN) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Cleara - GuruFocus
Form 8K Ocugen, Inc For: 6 August By Investing.com - Investing.com South Africa
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ... - Yahoo Finance
Ocugen, Inc. 2026: Revenue $1.49M, EPS ($0.07) — 10-Q Summary - TradingView
Ocugen (NASDAQ: OCGN) raises $112.5M via converts as losses hit $44.1M - Stock Titan
Ocugen, Inc. Announces Management Changes - marketscreener.com
Earnings call transcript: Ocugen posts Q2 2026 revenue beat as loss widens - Investing.com
OCGN: FDA cleared phase III for OCU410; cash runway extended to 2028 after $130M financing - TradingView
Ocugen Provides Business Update with Second Quarter 2026 Financial Results - Ocugen, Inc.
Ocugen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
Ocugen, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ocugen reports $1.49M Q2 revenue, $0.07 loss per share and $100.4M cash as of June 30, 2026 - TradingView
Ocugen: Q2 Earnings Snapshot - marketscreener.com
Ocugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing - Quiver Quantitative
Press Release: Ocugen Provides Business Update With Second Quarter 2026 Financial Results - Moomoo
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Ocugen Inc (2H51.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
FDA grants OCU410 regenerative medicine advanced therapy designation for geographic atrophy - AllSci
Ocugen to Present Modifier Gene Therapy Platform at Upcoming August 2026 Investor Conferences - Quiver Quantitative
FDA grants RMAT designation to Ocugen’s OCU410 for eye disease - Investing.com
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):